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Abstract
With a view to the application in oral controlled drug delivery systems, the formation of interpolyelectrolyte complexes (IPEC)
between chitosan (CS) and Eudragit L100 (L100) or Eudragit L100-55 (L100-55) was investigated at pH 6.0, using elementary anal-
ysis. The interaction or binding ratio of a unit molecule of CS with Eudragit L copolymers depends on the molecular weight of CS, and
changes from 1:0.85 to 1:1.22 (1.17 < u < 0.82) for L100 and from 1:1.69 to 1:1.26 (0.60 < u < 0.79) for L100-55, respectively. Based on
the results of FT-IR, the structure of the IPECs can change substantially as a function of pH (from 5.8 till 7.4). Swelling behavior of
physical mixtures (PM) is deﬁnitely diﬀerent, and potential interactions between the two polyelectrolytes were not observed. The release
of the model drug diclofenac sodium (DS) was signiﬁcantly delayed from tablets made up of the IPEC and can be modiﬁed by two ways:
choosing Eudragit L copolymer types and/or changing the molecular weight of CS in the IPECs composition.
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1. Introduction
Modiﬁcation of the properties of a polymer can be
obtained by copolymerisation or derivatisation, a strategy
that was successfully applied in the past. However, the
major drawback of this approach is that new chemical enti-
ties are introduced with an unknown toxicological proﬁle.
Before these products can be evaluated in animals and also
in human clinical trials, a lot of time and resources must be
spent to safety evaluation. A sound approach to overcome
this problem is the physical modiﬁcation of the polymer,
rather than the chemical. In this respect interpolyelectro-
lyte complexes (IPEC) may provide a valuable tool to
design drug delivery systems with speciﬁc physicochemical
properties.
IPEC with polysaccharides, obtained as precipitates on
mixing cationic with anionic polymers in aqueous solu-
tions, have been reported previously, mostly with partici-
pation of chitosan (CS) as polycation. The advantages
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Abbreviations: IPEC, interpolyelectrolyte complex; CS, chitosan; CSLW,
low molecular weight chitosan; CSMW, medium molecular weight chito-
san; CSHW, high molecular weight chitosan; MW, molecular weight; L100,
Eudragit L100; L100-55, Eudragit L100-55; PM, physical mixture of
the polymers; DS, diclofenac sodium; SIT, simulated the intestinal tract;
GIT, gastro-intestinal tract.
* Corresponding author. Department of Pharmaceutical, Toxicological
and Analytical Chemistry, State Medical University of Kazan, Butlerov
str., 49, 420012 Kazan, Tatarstan, Russian Federation. Tel.: +7 843
2360451, fax: +7 843 2360393.
E-mail address: mustaf@rambler.ru (R.I. Moustaﬁne).
www.elsevier.com/locate/ejpb
Available online at www.sciencedirect.com
European Journal of Pharmaceutics and Biopharmaceutics 70 (2008) 215–225
